ArticleNPJ precision oncology2022
MatchMiner: an open-source platform for cancer precision medicine.
Article in NPJ precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer.JCO precision oncology · 2023Pooled it
- Clinical Trial Notifications Triggered by Artificial Intelligence-Detected Cancer Progression: A Randomized Trial.JAMA network open · 2025Trial
- Assessing Quality Gaps and Clinician Perspectives on AI Integration in Colorectal Cancer NGS Pathways.Current oncology (Toronto, Ont.) · 2026Article
- AI-based multimodal integration of genomics and electronic health records.Nature reviews. Genetics · 2026Review
- From matching to facilitation: Reframing AI's role in clinical trial enrollment.Patterns (New York, N.Y.) · 2026Article
- Optimizing Precision Oncology: Structural Frameworks for Local MTB Integration and Outcome Assessment.Medical sciences (Basel, Switzerland) · 2026Review
- The role of AI in oncology: present applications and future horizons.NPJ precision oncology · 2026Review
- TrialMatchAI: an end-to-end AI-powered clinical trial recommendation system to streamline patient-to-trial matching.Nature communications · 2026Article
- Convergence of machine learning and genomics for precision oncology.Nature reviews. Cancer · 2026Review
- AI for clinical trials in oncology.ESMO real world data and digital oncology · 2026Review
- Article
- Informatics at the Frontier of Cancer Research.Cancer research · 2025Review
- CancerTrialMatch: a computational resource for the management of biomarker-based clinical trials at a community cancer center.Bioinformatics (Oxford, England) · 2025Article
- Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center's real-world approach.ESMO real world data and digital oncology · 2025Article
- Artificial intelligence methods available for cancer research.Frontiers of medicine · 2024Review
- Basket Trials: Past, Present, and Future.Annual review of cancer biology · 2024Article
- Identifying Oncology Clinical Trial Candidates Using Artificial Intelligence Predictions of Treatment Change: A Pilot Implementation Study.JCO precision oncology · 2024Article
- Matching Patients to Accelerate Clinical Trials (MPACT): Enabling Technology for Oncology Clinical Trial Workflow.Studies in health technology and informatics · 2024Article
- Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm.Cambridge prisms. Precision medicine · 2024Review
- OncoCTMiner: streamlining precision oncology trial matching via molecular profile analysis.Database : the journal of biological databases and curation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Widespread, comprehensive sequencing of patient tumors has facilitated the usage of precision medicine (PM) drugs to target specific genomic alterations. Therapeutic clinical trials are necessary to test new PM drugs to advance precision medicine, however, the abundance of patient sequencing data coupled with complex clinical trial eligibility has made it challenging to match patients to PM trials. To facilitate enrollment onto PM trials, we developed MatchMiner, an open-source platform to computationally match genomically profiled cancer patients to PM trials. Here, we describe MatchMiner's capabilities, outline its deployment at Dana-Farber Cancer Institute (DFCI), and characterize its impact on PM trial enrollment. MatchMiner's primary goals are to facilitate PM trial options for all patients and accelerate trial enrollment onto PM trials. MatchMiner can help clinicians find trial options for an individual patient or provide trial teams with candidate patients matching their trial's eligibility criteria. From March 2016 through March 2021, we curated 354 PM trials containing a broad range of genomic and clinical eligibility criteria and MatchMiner facilitated 166 trial consents (MatchMiner consents, MMC) for 159 patients. To quantify MatchMiner's impact on trial consent, we measured time from genomic sequencing report date to trial consent date for the 166 MMC compared to trial consents not facilitated by MatchMiner (non-MMC). We found MMC consented to trials 55 days (22%) earlier than non-MMC. MatchMiner has enabled our clinicians to match patients to PM trials and accelerated the trial enrollment process.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.